pharmjournalРазработка и регистрация лекарственных средствDrug development & registration2305-20662658-5049LLC «CPHA»10.33380/2305-2066-2019-8-1-14-22pharmjournal-643Research ArticleПОИСК И РАЗРАБОТКА НОВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВRESEARCH AND DEVELOPMENT OF NEW DRUG PRODUCTSНАНОАНТИТЕЛА: СТРОЕНИЕ, ПОЛУЧЕНИЕ, ПРИМЕНЕНИЕ (ОБЗОР)NANOBODIES: STRUCTURE, MANUFACTURING, APPLICATION (REVIEW)ШаталоваА. В.ShatalovaA. V.shatalova.anna.v@gmail.comЯкубоваА. С.YakubovaA. S.ПалимпсестовВ. В.PalimpsestovV. V.ЕсмагамбетовИ. Б.EsmagambetovI. B.ФГАОУ ВО «Российский университет дружбы народов» (РУДН)РоссияPeoples’ Friendship University of Russia (RUDN University)Russian FederationФГБОУ ВО «Московский педагогический государственный университет»РоссияMoscow Pedagogical State UniversityRussian FederationФГБУ «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н. Ф. Гамалеи» Министерства здравоохранения Российской ФедерацииРоссияFederal Research Centre for Epidemiology and Microbiology named after the honorary academician N. F. Gamaleya of the Ministry of Health of the Russian FederationRussian Federation201914022019811422Copyright © Шаталова А.В., Якубова А.С., Палимпсестов В.В., Есмагамбетов И.Б., 20192019Шаталова А.В., Якубова А.С., Палимпсестов В.В., Есмагамбетов И.Б.Shatalova A.V., Yakubova A.S., Palimpsestov V.V., Esmagambetov I.B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmjournal.ru/jour/article/view/643Введение

Введение. Однодоменные антитела (наноантитела) в отличие от классических иммуноглобулинов, представлены одним вариабельным доменом тяжелоцепочечного антитела. По сравнению с классическими IgG, наноантитела обладают такими качествами, как: высокая биологическая доступность, способность взаимодействовать с труднодоступными эпитопами, высокая растворимость, термостабильность, возможность получения в бактериальных системах экспрессии.

Текст

Текст. Цель статьи в описании структурных и функциональных свойств наноантител, а также их эффективного применения.

Заключение

Заключение. Области применения наноантител очень обширны: лабораторные исследования, диагностика и терапия онкологических, инфекционных, гематологических, воспалительных, аутоиммунных и нейродегенеративных заболеваний. В зависимости от целей применения, наноантитела легко модифицировать, присоединив другое наноантитело, необходимую молекулу или радиоактивную метку. Наноантитела обладают огромным потенциалом для применения в диагностике, терапии и медицине.

Introduction

Introduction. Single-domain antibodies (nanobodies) are composed of the heavy-chain variable domain only. Compared to conventional immunoglobulins G (IgG) nanobodies have such qualities as: high bioavailability, ability to bind epitopes that are difficult to reach, high solubility and thermal stability, etc. Nanobodies can be easily manufactured in microorganisms (E. coli) to significantly save on cost.

Text

Text. Goal of the paper consists of the description of structural and functional properties of nanobodies and its effective application.

Conclusion

Conclusion. Nanobodies can be used in many fields of medicine and biotechnology such as research, diagnostics and therapy of oncology, infectious, hematological, inflammatory, autoimmune and neurological diseases. They can also be easily modified using another nanobody, molecules or radioactive mark as necessary. Nanobodies have huge potential for applications in diagnostics, therapy and medicine.

наноантителаоднодоменные антителаVHHnanobodiessingle domain antibodiesVHHReferencesВятчанин А. С., Тиллиб С. В. Модификации процедуры фагового дисплея для повышения эффективности селекции антигенсвязывающих доменов особых одноцепочечных верблюжьих антител. Биотехнология. 2008; 4: 22–27.Vjatchanin A. S., Tillib S. V. Modifications of the phage display procedure to increase the efficiency of selection of antigen-binding domains of specific single-chain camel antibodies. Biotechnology. 2008; 4: 22–27 (In Russ.).Манько В. М., Девришов Д. А. Ветеринарная иммунология. Фундаментальные основы: Учебник. М: Издательство «Агровет». 2011; 752 c.Man’ko V. M., Devrishov D. A. Veterinary immunology. Fundamentals: Textbook. M: Publishing «Agrovet». 2011; 752 р. (In Russ.).Ярилин. А. А. Иммунология: Учебник. М.: ГЭОТАР-Медиа. 2010; 752 c.Yarilin. A. A. Immunology: Textbook. M.: GEOTAR-Media. 2010; 752 р. (In Russ.).Abbady A. Q. et al. Evaluation of a nanobody phage display library constructed from a Brucella-immunised camel. Veterinaty Immunology and Immunopathology. 2011; 142: 49–56.Abbady A. Q. et al. Evaluation of a nanobody phage display library constructed from a Brucella-immunised camel. Veterinaty Immunology and Immunopathology. 2011; 142: 49–56.Delanote V. et al. Ablynx. 2014. Challenging and intractable targets. Poster: Characterization of Anti-Kv1.3 Nanobodies and activity in Inflammatory model systems. Available at: http://www.ablynx.com/technology-innovation/nanobodies-competitive-features/ (accessed 20.03.18).Delanote V. et al. Ablynx. 2014. Challenging and intractable targets. Poster: Characterization of Anti-Kv1.3 Nanobodies and activity in Inflammatory model systems. Available at: http://www.ablynx.com/technology-innovation/nanobodies-competitive-features/ (accessed 20.03.18).Ablynx. 2015. Press Releases: Ablynx Initiates Phase II SLE Study With Its Anti-IL–6R Nanobody, Partnered With Abbvie. Available at: http://www.ablynx.com/news/press-releases/?pyear=2015&lang=en (accessed 22.03.18)Ablynx. 2015. Press Releases: Ablynx Initiates Phase II SLE Study With Its Anti-IL–6R Nanobody, Partnered With Abbvie. Available at: http://www.ablynx.com/news/press-releases/?pyear=2015&lang=en (accessed 22.03.18)Arbabi-Ghahroudi M., Tanha J., MacKenzie R. Prokaryotic expression of antibodies. Cancer Metastasis Rev. 2005; 24(4): 501–519.Arbabi-Ghahroudi M., Tanha J., MacKenzie R. Prokaryotic expression of antibodies. Cancer Metastasis Rev. 2005; 24(4): 501–519.Blanc M.R. et al. A one-step exclusion-binding procedure for the purification of functional heavy-chain and mammalian-type γ-globulins from camelid sera. Biotechnol. Appl. Biochem. 2009;54(4): 207–212.Blanc M.R. et al. A one-step exclusion-binding procedure for the purification of functional heavy-chain and mammalian-type γ-globulins from camelid sera. Biotechnol. Appl. Biochem. 2009;54(4): 207–212.Brissett R., Neil I. Goldsteine. The use of phage display peptide libraries for basic and translational research. Methods in Molecular Biology. 2007; 383: 203–213.Brissett R., Neil I. Goldsteine. The use of phage display peptide libraries for basic and translational research. Methods in Molecular Biology. 2007; 383: 203–213.Chakravarty R. et al. Nanobody: The «Magic Bullet» for Molecular Imaging? Theranostics. 2014; 4(4): 386–398.Chakravarty R. et al. Nanobody: The «Magic Bullet» for Molecular Imaging? Theranostics. 2014; 4(4): 386–398.De Genst E. et al. Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc. Natl. Acad. Sci. 2006; 103(12): 4586–4591.De Genst E. et al. Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc. Natl. Acad. Sci. 2006; 103(12): 4586–4591.Debets M.F. et al. Nanobody-functionalized polymersomes for tumorvessel targeting. Macromolecular Bioscience. 2013; 13: 938–945.Debets M.F. et al. Nanobody-functionalized polymersomes for tumorvessel targeting. Macromolecular Bioscience. 2013; 13: 938–945.Desmyter A. et al. Camelid nanobodies: killing two birds with one stone. Current Opinion in Structural Biology. 2015; 32: 1 – 8.Desmyter A. et al. Camelid nanobodies: killing two birds with one stone. Current Opinion in Structural Biology. 2015; 32: 1 – 8.Detalle L. et al. Generation and characterisation of ALX-0171, a potent novel therapeutic nanobody for the treatment of respiratory syncytial virus infection. Antimicrobal Agents and Chemotherapy. 2015; 60: 6–13.Detalle L. et al. Generation and characterisation of ALX-0171, a potent novel therapeutic nanobody for the treatment of respiratory syncytial virus infection. Antimicrobal Agents and Chemotherapy. 2015; 60: 6–13.Ellen R. Goldman et al. Enhancing Stability of Camelid and Shark Single Domain Antibodies: An Overview. Front Immunol. 2017; 8: 865.Ellen R. Goldman et al. Enhancing Stability of Camelid and Shark Single Domain Antibodies: An Overview. Front Immunol. 2017; 8: 865.Estell D. et al. Adapting industry practices for the rapid, largescale manufacture of pharmaceutical proteins. The Bridge. 2006; 36(3):39–44.Estell D. et al. Adapting industry practices for the rapid, largescale manufacture of pharmaceutical proteins. The Bridge. 2006; 36(3):39–44.Gonzalez-Sapienza G. et al. Single-Domain Antibodies As Versatile Affinity Reagents for Analytical and Diagnostic Applications. Front Immunol. 2017; 8: 977.Gonzalez-Sapienza G. et al. Single-Domain Antibodies As Versatile Affinity Reagents for Analytical and Diagnostic Applications. Front Immunol. 2017; 8: 977.Hamers-Casterman C. et al. Naturally occurring antibodies devoid of light chains. Nature. 1993; 363: 446–448.Hamers-Casterman C. et al. Naturally occurring antibodies devoid of light chains. Nature. 1993; 363: 446–448.Harmsen M. M., De Haard H. J. Properties, production, and applications of camelid single-domain antibody fragments. Appl. Microbiol. Biotechnol. 2007; 77(1): 13–22.Harmsen M. M., De Haard H. J. Properties, production, and applications of camelid single-domain antibody fragments. Appl. Microbiol. Biotechnol. 2007; 77(1): 13–22.Harmsen M.M. et al. Llama heavy-chain V regions consist of at least four distinct subfamilies revealing novel sequence features. Mol. Immunol. 2000; 37(10): 579–590.Harmsen M.M. et al. Llama heavy-chain V regions consist of at least four distinct subfamilies revealing novel sequence features. Mol. Immunol. 2000; 37(10): 579–590.Hassanzadeh-Ghassabeh G. et al. Nanobodies and their potential applications. Nanomedicine (Lond). 2013; 8(6): 1013–1026. 2Hassanzadeh-Ghassabeh G. et al. Nanobodies and their potential applications. Nanomedicine (Lond). 2013; 8(6): 1013–1026.Hu Y., Liu C., Muyldermans S.Nanobody-Based Delivery Systems for Diagnosis and Targeted Tumor Therapy. Frontiers in immunology. 2017; 8: 1442.Hu Y., Liu C., Muyldermans S.Nanobody-Based Delivery Systems for Diagnosis and Targeted Tumor Therapy. Frontiers in immunology. 2017; 8: 1442.Lauwereys M., Ghahroudi M. A. et al. Potent enzyme inhibitors derived from dromedary heavychain antibodies. EMBO J. 1998; 17: 3512–3520.Lauwereys M., Ghahroudi M. A. et al. Potent enzyme inhibitors derived from dromedary heavychain antibodies. EMBO J. 1998; 17: 3512–3520.Maass D. R. et al. Alpaca (Lama pacos) as a convenient source of recombinant camelid heavy chain antibodies (VHHs). J. Immunol. Methods. 2007; 324: 13–25.Maass D. R. et al. Alpaca (Lama pacos) as a convenient source of recombinant camelid heavy chain antibodies (VHHs). J. Immunol. Methods. 2007; 324: 13–25.Mullard A. 2014 FDA drug approvals. Nature Reviews Drug Discovery. 2015; 14: 77–81.Mullard A. 2014 FDA drug approvals. Nature Reviews Drug Discovery. 2015; 14: 77–81.Muyldermans S. et al. Camelid immunoglobulins and nanobody technology. Vet. Immunol. Immunopathol. 2009; 128: 178–183.Muyldermans S. et al. Camelid immunoglobulins and nanobody technology. Vet. Immunol. Immunopathol. 2009; 128: 178–183.Muyldernans S. Nanobodies: Natural Single-Domain Antibodies. Annu.Rev.Biochem. 2013. V.; 82: 17.1–17.23.Muyldernans S. Nanobodies: Natural Single-Domain Antibodies. Annu.Rev.Biochem. 2013. V.; 82: 17.1–17.23.Nguen V. K. et al. Camel heavy-chain antibodies: diverse germline VHH and specific mechanisms enlarge the antigen-binding repertoire. EMBO J. 2000; 19(5): 921–930.Nguen V. K. et al. Camel heavy-chain antibodies: diverse germline VHH and specific mechanisms enlarge the antigen-binding repertoire. EMBO J. 2000; 19(5): 921–930.Nguyen V. K. et al. The Specific Variable Domain of Camel heavychain antibodies is encoded in the germline. J. Mol. Biol. 1998; 275(3): 413–418.Nguyen V. K. et al. The Specific Variable Domain of Camel heavychain antibodies is encoded in the germline. J. Mol. Biol. 1998; 275(3): 413–418.Nguyen V. K., Desmyter A., Muyldermans S. Functional heavy-chain antibodies in Camelidae. Adv. Immunol. 2001; 79: 261–296.Nguyen V. K., Desmyter A., Muyldermans S. Functional heavy-chain antibodies in Camelidae. Adv. Immunol. 2001; 79: 261–296.Nuttall S. D. et al. Isolation of a new antigen receptor from wobbegong sharks, and use as a scaffold for the display of protein loop libraries. Mol. Immunol. 2001; 38(4): 313–326.Nuttall S. D. et al. Isolation of a new antigen receptor from wobbegong sharks, and use as a scaffold for the display of protein loop libraries. Mol. Immunol. 2001; 38(4): 313–326.Oriol Sunyer J. Evolutionary and Functional Relationships of B Cells from Fish and Mammals: Insights into their Novel Roles in Phagocytosis and Presentation of Particulate Antigen. Infect Disord Drug Targets. 2012; 12(3): 200–212.Oriol Sunyer J. Evolutionary and Functional Relationships of B Cells from Fish and Mammals: Insights into their Novel Roles in Phagocytosis and Presentation of Particulate Antigen. Infect Disord Drug Targets. 2012; 12(3): 200–212.Pardon E. A. et al. A general protocol for the generation of Nanobodies for structural biology. Nat Protocols. 2014; 9(3): 674–693.Pardon E. A. et al. A general protocol for the generation of Nanobodies for structural biology. Nat Protocols. 2014; 9(3): 674–693.Pleiner T., Bates M. Nanobodies: site-specific labeling for superresolution imaging, rapid epitope-mapping and native protein complex isolation. Elife. 2015; 4.Pleiner T., Bates M. Nanobodies: site-specific labeling for superresolution imaging, rapid epitope-mapping and native protein complex isolation. Elife. 2015; 4.R. van der Linden et al. Induction of immune responses and molecular cloning of the heavy chain antibody repertoire of Lama glama. J. Immunol. Methods. 2000; 240(1-2); 185–195.R. van der Linden et al. Induction of immune responses and molecular cloning of the heavy chain antibody repertoire of Lama glama. J. Immunol. Methods. 2000; 240(1-2); 185–195.Rahbarizadeh F. et al. Over expression of anti-MUC1 single-domain antibody fragments in the yeast Pichia pastoris. Mol. Immunol. 2006; 43(5): 426–435.Rahbarizadeh F. et al. Over expression of anti-MUC1 single-domain antibody fragments in the yeast Pichia pastoris. Mol. Immunol. 2006; 43(5): 426–435.Ryman J. T., Meibohm B. Pharmacokinetics of Monoclonal Antibodies. CPT Pharmacometrics and System Pharmacology. 2017; 6(9): 576–588.Ryman J. T., Meibohm B. Pharmacokinetics of Monoclonal Antibodies. CPT Pharmacometrics and System Pharmacology. 2017; 6(9): 576–588.Saerens D. et al. Antibody fragments as probe in biosensor development. Sensors (Basel). 2008; 8(8): 4669–4686.Saerens D. et al. Antibody fragments as probe in biosensor development. Sensors (Basel). 2008; 8(8): 4669–4686.Seligmann M. et al. Heavy chain diseases: current findings and concepts. Immunological Rev. 1979; 48: 145–167.Seligmann M. et al. Heavy chain diseases: current findings and concepts. Immunological Rev. 1979; 48: 145–167.Sharkey R. M., Goldenberg D. M. Cancer radioimmunotherapy. Immunotherapy. 2011; 3: 349–370.Sharkey R. M., Goldenberg D. M. Cancer radioimmunotherapy. Immunotherapy. 2011; 3: 349–370.Steeland S. et al. Nanobodies as therapeutics: big opportunities for small antibodies. Drug Discov Today. 2016; 21(7): 1076–1113.Steeland S. et al. Nanobodies as therapeutics: big opportunities for small antibodies. Drug Discov Today. 2016; 21(7): 1076–1113.Tilib S. V. «Camel Nanoantibody» is an Efficient Tool for Research, Diagnostics and Therapy. Molecular Biology. 2011; 45(1): 66–73.Tilib S. V. «Camel Nanoantibody» is an Efficient Tool for Research, Diagnostics and Therapy. Molecular Biology. 2011; 45(1): 66–73.Van Heeke G. et al. Nanobodies as inhaled biotherapeutics for lung diseases. Pharmacol Ther. 2017; 169: 47–56.Van Heeke G. et al. Nanobodies as inhaled biotherapeutics for lung diseases. Pharmacol Ther. 2017; 169: 47–56.Woolven B. P. et al. The structure of the llama heavy chain constant genes reveals a mechanism for heavy-chain antibody formation. Immunogenetics. 1999; 50(1-2): 98–101.Woolven B. P. et al. The structure of the llama heavy chain constant genes reveals a mechanism for heavy-chain antibody formation. Immunogenetics. 1999; 50(1-2): 98–101.Yan J. et al. Characterization and applications of Nanobodies against human procalcitonin selected from a novel naïve Nanobody phage display library. J. Nanobiotechnology. 2015; 6: 13–33.Yan J. et al. Characterization and applications of Nanobodies against human procalcitonin selected from a novel naïve Nanobody phage display library. J. Nanobiotechnology. 2015; 6: 13–33.Yardehnavi N. et al. A camelid antibody candidate for development of a therapeutic agent against Hemiscorpius lepturus envenomation. Faseb J. 2014; 28(9): 4004–4014.Yardehnavi N. et al. A camelid antibody candidate for development of a therapeutic agent against Hemiscorpius lepturus envenomation. Faseb J. 2014; 28(9): 4004–4014.Zou T. et al. Nanobody-functionalized PEG-b-PCL polymersomes and their targeting study. Journal of Biotechnology. 2015; 214: 147–155.Zou T. et al. Nanobody-functionalized PEG-b-PCL polymersomes and their targeting study. Journal of Biotechnology. 2015; 214: 147–155.

The authors declare that there are no conflicts of interest present.